Development and validation of a risk prediction model for in-hospital mortality after transcatheter aortic valve replacement

Steering Committee of the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry

Research output: Contribution to journalArticle

119 Citations (Scopus)

Abstract

IMPORTANCE: Patient selection for transcatheter aortic valve replacement (TAVR) should include assessment of the risks of TAVR compared with surgical aortic valve replacement (SAVR). Existing SAVR risk models accurately predict the risks for the population undergoing SAVR, but comparable models to predict risk for patients undergoing TAVR are currently not available and should be derived from a population that underwent TAVR. OBJECTIVE: To use a national population of patients undergoing TAVR to develop a statistical model that will predict in-hospital mortality after TAVR. DESIGN, SETTING, AND PARTICIPANTS: Patient data were obtained from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy (STS/ACC TVT) Registry. The model was developed from 13 718 consecutive US patients undergoing TAVR in centers participating in the STS/ACC TVT Registry from November 1,2011, to February 28,2014. Validation was conducted using 6868 records of consecutive patients undergoing TAVR from March 1 to October 8,2014. Covariates were selected through a process of expert opinion and statistical analysis. The association between in-hospital mortality and baseline covariates was estimated using logistic regression. The final set of predictors was selected via stepwise variable selection. Data were collected and analyzed from November 1,2011, to February 28,2014. MAIN OUTCOMES AND MEASURES: In-hospital TAVR mortality. RESULTS: The development sample included 13 718 patient records from 265 participant sites (of 13 672 with data available, 6680 men [48.9%]; 6992 women [51.1%]; mean [SD] age, 82.1 [8.3] years). The final validation cohort included 6868 patients from 314 participating centers (3554 men [51.7%]; 3314 women [48.3%]; mean [SD]age, 81.6 [8.8] years). In-hospital mortality occurred in 730 patients (5.3%). The C statistic for discrimination was 0.67 (95% CI, 0.65-0.69) in the development group and 0.66 (95% CI, 0.62-0.69) in the validation group. The final model covariates (reported as odds ratios; 95% CIs) were age (1.13; 1.06-1.20), glomerular filtration rate per 5-U increments (0.93; 0.91-0.95), hemodialysis (3.25; 2.42-4.37), New York Heart Association functional class IV (1.25; 1.03-1.52), severe chronic lung disease (1.67; 1.35-2.05), nonfemoral access site (1.96; 1.65-2.33), and procedural acuity categories 2 (1.57; 1.20-2.05), 3 (2.70; 2.05-3.55), and 4 (3.34; 1.59-702). Calibration analysis demonstrated no significant difference between the model (predicted vs observed) calibration line (-0.18 and 0.97 for intercept and slope, respectively) compared with the ideal calibration line. CONCLUSIONS AND RELEVANCE: Data from the STS/ACC TVT Registry have been used to develop a predictive model of in-hospital mortality for patients undergoing TAVR. Validation based on a population of patient records not used in model development demonstrates discrimination and calibration indices that are more favorable than other models used in populations with TAVR. This model should be a valuable adjunct for patient counseling, local quality improvement, and national monitoring for appropriateness of selection of patients for TAVR.

Original languageEnglish (US)
Pages (from-to)46-52
Number of pages7
JournalJAMA cardiology
Volume1
Issue number1
DOIs
StatePublished - Apr 1 2016

Fingerprint

Hospital Mortality
Calibration
Aortic Valve
Surgical Instruments
Registries
Population
Cardiology
Patient Selection
Transcatheter Aortic Valve Replacement
Thorax
Expert Testimony
Statistical Models
Quality Improvement
Glomerular Filtration Rate
Lung Diseases
Renal Dialysis
Counseling
Chronic Disease
Therapeutics
Logistic Models

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Steering Committee of the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry (2016). Development and validation of a risk prediction model for in-hospital mortality after transcatheter aortic valve replacement. JAMA cardiology, 1(1), 46-52. https://doi.org/10.1001/jamacardio.2015.0326

Development and validation of a risk prediction model for in-hospital mortality after transcatheter aortic valve replacement. / Steering Committee of the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry.

In: JAMA cardiology, Vol. 1, No. 1, 01.04.2016, p. 46-52.

Research output: Contribution to journalArticle

Steering Committee of the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry 2016, 'Development and validation of a risk prediction model for in-hospital mortality after transcatheter aortic valve replacement', JAMA cardiology, vol. 1, no. 1, pp. 46-52. https://doi.org/10.1001/jamacardio.2015.0326
Steering Committee of the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. Development and validation of a risk prediction model for in-hospital mortality after transcatheter aortic valve replacement. JAMA cardiology. 2016 Apr 1;1(1):46-52. https://doi.org/10.1001/jamacardio.2015.0326
Steering Committee of the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. / Development and validation of a risk prediction model for in-hospital mortality after transcatheter aortic valve replacement. In: JAMA cardiology. 2016 ; Vol. 1, No. 1. pp. 46-52.
@article{e98d39b0677248faa3aa403f70762fb5,
title = "Development and validation of a risk prediction model for in-hospital mortality after transcatheter aortic valve replacement",
abstract = "IMPORTANCE: Patient selection for transcatheter aortic valve replacement (TAVR) should include assessment of the risks of TAVR compared with surgical aortic valve replacement (SAVR). Existing SAVR risk models accurately predict the risks for the population undergoing SAVR, but comparable models to predict risk for patients undergoing TAVR are currently not available and should be derived from a population that underwent TAVR. OBJECTIVE: To use a national population of patients undergoing TAVR to develop a statistical model that will predict in-hospital mortality after TAVR. DESIGN, SETTING, AND PARTICIPANTS: Patient data were obtained from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy (STS/ACC TVT) Registry. The model was developed from 13 718 consecutive US patients undergoing TAVR in centers participating in the STS/ACC TVT Registry from November 1,2011, to February 28,2014. Validation was conducted using 6868 records of consecutive patients undergoing TAVR from March 1 to October 8,2014. Covariates were selected through a process of expert opinion and statistical analysis. The association between in-hospital mortality and baseline covariates was estimated using logistic regression. The final set of predictors was selected via stepwise variable selection. Data were collected and analyzed from November 1,2011, to February 28,2014. MAIN OUTCOMES AND MEASURES: In-hospital TAVR mortality. RESULTS: The development sample included 13 718 patient records from 265 participant sites (of 13 672 with data available, 6680 men [48.9{\%}]; 6992 women [51.1{\%}]; mean [SD] age, 82.1 [8.3] years). The final validation cohort included 6868 patients from 314 participating centers (3554 men [51.7{\%}]; 3314 women [48.3{\%}]; mean [SD]age, 81.6 [8.8] years). In-hospital mortality occurred in 730 patients (5.3{\%}). The C statistic for discrimination was 0.67 (95{\%} CI, 0.65-0.69) in the development group and 0.66 (95{\%} CI, 0.62-0.69) in the validation group. The final model covariates (reported as odds ratios; 95{\%} CIs) were age (1.13; 1.06-1.20), glomerular filtration rate per 5-U increments (0.93; 0.91-0.95), hemodialysis (3.25; 2.42-4.37), New York Heart Association functional class IV (1.25; 1.03-1.52), severe chronic lung disease (1.67; 1.35-2.05), nonfemoral access site (1.96; 1.65-2.33), and procedural acuity categories 2 (1.57; 1.20-2.05), 3 (2.70; 2.05-3.55), and 4 (3.34; 1.59-702). Calibration analysis demonstrated no significant difference between the model (predicted vs observed) calibration line (-0.18 and 0.97 for intercept and slope, respectively) compared with the ideal calibration line. CONCLUSIONS AND RELEVANCE: Data from the STS/ACC TVT Registry have been used to develop a predictive model of in-hospital mortality for patients undergoing TAVR. Validation based on a population of patient records not used in model development demonstrates discrimination and calibration indices that are more favorable than other models used in populations with TAVR. This model should be a valuable adjunct for patient counseling, local quality improvement, and national monitoring for appropriateness of selection of patients for TAVR.",
author = "{Steering Committee of the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry} and Edwards, {Fred H.} and Cohen, {David J.} and O'Brien, {Sean M.} and Peterson, {Eric D.} and Mack, {Michael J.} and Shahian, {David M.} and Grover, {Frederick L.} and Tuzcu, {E. Murat} and Thourani, {Vinod H.} and John Carroll and Brennan, {J. Matthew} and Brindis, {Ralph G.} and John Rumsfeld and David Holmes",
year = "2016",
month = "4",
day = "1",
doi = "10.1001/jamacardio.2015.0326",
language = "English (US)",
volume = "1",
pages = "46--52",
journal = "JAMA Cardiology",
issn = "2380-6583",
publisher = "American Medical Association",
number = "1",

}

TY - JOUR

T1 - Development and validation of a risk prediction model for in-hospital mortality after transcatheter aortic valve replacement

AU - Steering Committee of the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry

AU - Edwards, Fred H.

AU - Cohen, David J.

AU - O'Brien, Sean M.

AU - Peterson, Eric D.

AU - Mack, Michael J.

AU - Shahian, David M.

AU - Grover, Frederick L.

AU - Tuzcu, E. Murat

AU - Thourani, Vinod H.

AU - Carroll, John

AU - Brennan, J. Matthew

AU - Brindis, Ralph G.

AU - Rumsfeld, John

AU - Holmes, David

PY - 2016/4/1

Y1 - 2016/4/1

N2 - IMPORTANCE: Patient selection for transcatheter aortic valve replacement (TAVR) should include assessment of the risks of TAVR compared with surgical aortic valve replacement (SAVR). Existing SAVR risk models accurately predict the risks for the population undergoing SAVR, but comparable models to predict risk for patients undergoing TAVR are currently not available and should be derived from a population that underwent TAVR. OBJECTIVE: To use a national population of patients undergoing TAVR to develop a statistical model that will predict in-hospital mortality after TAVR. DESIGN, SETTING, AND PARTICIPANTS: Patient data were obtained from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy (STS/ACC TVT) Registry. The model was developed from 13 718 consecutive US patients undergoing TAVR in centers participating in the STS/ACC TVT Registry from November 1,2011, to February 28,2014. Validation was conducted using 6868 records of consecutive patients undergoing TAVR from March 1 to October 8,2014. Covariates were selected through a process of expert opinion and statistical analysis. The association between in-hospital mortality and baseline covariates was estimated using logistic regression. The final set of predictors was selected via stepwise variable selection. Data were collected and analyzed from November 1,2011, to February 28,2014. MAIN OUTCOMES AND MEASURES: In-hospital TAVR mortality. RESULTS: The development sample included 13 718 patient records from 265 participant sites (of 13 672 with data available, 6680 men [48.9%]; 6992 women [51.1%]; mean [SD] age, 82.1 [8.3] years). The final validation cohort included 6868 patients from 314 participating centers (3554 men [51.7%]; 3314 women [48.3%]; mean [SD]age, 81.6 [8.8] years). In-hospital mortality occurred in 730 patients (5.3%). The C statistic for discrimination was 0.67 (95% CI, 0.65-0.69) in the development group and 0.66 (95% CI, 0.62-0.69) in the validation group. The final model covariates (reported as odds ratios; 95% CIs) were age (1.13; 1.06-1.20), glomerular filtration rate per 5-U increments (0.93; 0.91-0.95), hemodialysis (3.25; 2.42-4.37), New York Heart Association functional class IV (1.25; 1.03-1.52), severe chronic lung disease (1.67; 1.35-2.05), nonfemoral access site (1.96; 1.65-2.33), and procedural acuity categories 2 (1.57; 1.20-2.05), 3 (2.70; 2.05-3.55), and 4 (3.34; 1.59-702). Calibration analysis demonstrated no significant difference between the model (predicted vs observed) calibration line (-0.18 and 0.97 for intercept and slope, respectively) compared with the ideal calibration line. CONCLUSIONS AND RELEVANCE: Data from the STS/ACC TVT Registry have been used to develop a predictive model of in-hospital mortality for patients undergoing TAVR. Validation based on a population of patient records not used in model development demonstrates discrimination and calibration indices that are more favorable than other models used in populations with TAVR. This model should be a valuable adjunct for patient counseling, local quality improvement, and national monitoring for appropriateness of selection of patients for TAVR.

AB - IMPORTANCE: Patient selection for transcatheter aortic valve replacement (TAVR) should include assessment of the risks of TAVR compared with surgical aortic valve replacement (SAVR). Existing SAVR risk models accurately predict the risks for the population undergoing SAVR, but comparable models to predict risk for patients undergoing TAVR are currently not available and should be derived from a population that underwent TAVR. OBJECTIVE: To use a national population of patients undergoing TAVR to develop a statistical model that will predict in-hospital mortality after TAVR. DESIGN, SETTING, AND PARTICIPANTS: Patient data were obtained from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy (STS/ACC TVT) Registry. The model was developed from 13 718 consecutive US patients undergoing TAVR in centers participating in the STS/ACC TVT Registry from November 1,2011, to February 28,2014. Validation was conducted using 6868 records of consecutive patients undergoing TAVR from March 1 to October 8,2014. Covariates were selected through a process of expert opinion and statistical analysis. The association between in-hospital mortality and baseline covariates was estimated using logistic regression. The final set of predictors was selected via stepwise variable selection. Data were collected and analyzed from November 1,2011, to February 28,2014. MAIN OUTCOMES AND MEASURES: In-hospital TAVR mortality. RESULTS: The development sample included 13 718 patient records from 265 participant sites (of 13 672 with data available, 6680 men [48.9%]; 6992 women [51.1%]; mean [SD] age, 82.1 [8.3] years). The final validation cohort included 6868 patients from 314 participating centers (3554 men [51.7%]; 3314 women [48.3%]; mean [SD]age, 81.6 [8.8] years). In-hospital mortality occurred in 730 patients (5.3%). The C statistic for discrimination was 0.67 (95% CI, 0.65-0.69) in the development group and 0.66 (95% CI, 0.62-0.69) in the validation group. The final model covariates (reported as odds ratios; 95% CIs) were age (1.13; 1.06-1.20), glomerular filtration rate per 5-U increments (0.93; 0.91-0.95), hemodialysis (3.25; 2.42-4.37), New York Heart Association functional class IV (1.25; 1.03-1.52), severe chronic lung disease (1.67; 1.35-2.05), nonfemoral access site (1.96; 1.65-2.33), and procedural acuity categories 2 (1.57; 1.20-2.05), 3 (2.70; 2.05-3.55), and 4 (3.34; 1.59-702). Calibration analysis demonstrated no significant difference between the model (predicted vs observed) calibration line (-0.18 and 0.97 for intercept and slope, respectively) compared with the ideal calibration line. CONCLUSIONS AND RELEVANCE: Data from the STS/ACC TVT Registry have been used to develop a predictive model of in-hospital mortality for patients undergoing TAVR. Validation based on a population of patient records not used in model development demonstrates discrimination and calibration indices that are more favorable than other models used in populations with TAVR. This model should be a valuable adjunct for patient counseling, local quality improvement, and national monitoring for appropriateness of selection of patients for TAVR.

UR - http://www.scopus.com/inward/record.url?scp=85014498372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014498372&partnerID=8YFLogxK

U2 - 10.1001/jamacardio.2015.0326

DO - 10.1001/jamacardio.2015.0326

M3 - Article

C2 - 27437653

AN - SCOPUS:85014498372

VL - 1

SP - 46

EP - 52

JO - JAMA Cardiology

JF - JAMA Cardiology

SN - 2380-6583

IS - 1

ER -